Efficacy and safety of acupuncture in the treatment of pain in patients with hepatocellular carcinoma: A protocol of a randomized, single-blind, placebo-controlled clinical trial
- Registration Number
- TCTR20220626001
- Lead Sponsor
- Zhilin Zhou
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 90
1.Patients who are in accordance with the diagnosis of HCC (the diagnostic criteria refer to Guidelines for diagnosis and treatment of HCC (Version 2019)
2. Aged: 18 to 75 years old, stable and conscious;
3. Patients who have moderate and severe pain, and the 11-point numerical rating scale (NRS) score greater than 4
4. Patients whose expected survival is greater than 6 months;
5.Patients who have strong compliance and have signed informed consent.
1. Patients who are accompanied by infectious diseases, diseases of blood system;
2. Patients who have history of acupuncture syncope;
3. Women in pregnancy or lactation;
4. Patients who have pain associated with causes other than HCC;
5. Skin ulceration at the needling site.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 11-point numerical rating scale (NRS) 14 days Pain will be measured from 0 to 10, with 0 being no pain and 10 being severe pain.
- Secondary Outcome Measures
Name Time Method Times of morphine use 4 weeks the research assistant will count the total times of morphine use in both groups at the end of treatment